Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lloyd Aiello

Ophthalmology Boston, MA Medical Doctor

NPI 1588622104 CMS profile 162751

1 Joslin Place, Joslin Diabetes Center, Boston, MA 02215

Open in the dashboard

General payments

$89,570

33 records reported · program years 2019–2025

Research payments

$45,603

Paid to them · 17 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,050,006 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Lloyd Aiello of Boston, MA is reported in the CMS Open Payments database as having received $89,570 across 33 general payments and $45,603 in research payments paid to them. Separately, studies naming them as principal investigator received $3,050,006 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 Research $7,860 2
2024 Research $23,863 6
2023 General $18,957 7
2023 Research $1,190 1
2022 General $3,400 2
2022 Research $3,780 1
2021 General $1,900 2
2021 Research $2,160 2
2020 Research $6,750 5
2019 General $65,313 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lloyd Aiello
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Lloyd Aiello were reported at $0. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Lloyd Aiello Ophthalmology median Middle half National median
2019 $65,313 $258 $104–$655 $163
2020 $0 $126 $45–$321 $114
2021 $1,900 $205 $76–$534 $132
2022 $3,400 $266 $100–$678 $149
2023 $18,957 $308 $117–$745 $160
2024 $0 $340 $127–$846 $164
2025 $0 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk AS $64,361 15 payments
  2. Novo Nordisk Inc $19,154 11 payments
  3. Optos, Inc. $2,800 1 payment
  4. Genentech, Inc. $1,960 1 payment
  5. Samsung Bioepis Co., Ltd. $1,150 2 payments
  6. Optos PLC $145 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $81,586 11 payments
  2. Travel and Lodging $3,835 14 payments
  3. Honoraria $2,800 1 payment
  4. Food and Beverage $1,264 6 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $85 1 payment
Research payments came from Research payments · program years 2019–2025
  1. Novo Nordisk AS $45,603 17 payments

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

64

Median for Ophthalmology: 891

Drug cost

$1,741

Median for Ophthalmology: $68,233

Branded share of claims

0%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Timolol Maleate Generic 29 $1,325
Latanoprost Generic 35 $416

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$36,926

Medicare's payments for the services billed

Medicare patients

188

Average age 75

Services billed

592

104 women, 84 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Chronic kidney disease 41%
Arthritis 38%
Ischemic heart disease 35%
Heart failure 21%
Depression 21%
Osteoporosis 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

50 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record